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Abstract
The human genome contains multiple copies of retrovirus genomes known as endogenous retroviruses (ERVs) that
have entered the germ-line at some point in evolution. Several of these proviruses have retained (partial) coding
capacity, so that a number of viral proteins or even virus particles are expressed under various conditions. Human
ERVs (HERVs) belong to the beta-, gamma-, or spuma- retrovirus groups. Endogenous delta- and lenti- viruses are
notably absent in humans, although endogenous lentivirus genomes have been found in lower primates.
Exogenous retroviruses that currently form a health threat to humans intriguingly belong to those absent groups.
The best studied of the two infectious human retroviruses is the lentivirus human immunodeficiency virus (HIV)
which has an overwhelming influence on its host by infecting cells of the immune system. One HIV-induced
change is the induction of HERV transcription, often leading to induced HERV protein expression. This review will
discuss the potential HIV-HERV interactions.
Several studies have suggested that HERV proteins are unlikely to complement defective HIV virions, nor is HIV able
to package HERV transcripts, probably due to low levels of sequence similarity. It is unclear whether the expression
of HERVs has a negative, neutral, or positive influence on HIV-AIDS disease progression. A positive effect was
recently reported by the specific expression of HERVs in chronically HIV-infected patients, which results in the
presentation of HERV-derived peptides to CD8
+ T-cells. These cytotoxic T-cells were not tolerant to HERV peptides,
as would be expected for self-antigens, and consequently lysed the HIV-infected, HERV-presenting cells. This novel
mechanism could control HIV replication and result in a low plasma viral load. The possibility of developing a
vaccination strategy based on these HERV peptides will be discussed.
Review
Retroviruses are unique among the viridae by inserting
their genome into the host cellular DNA as an essential
step in the viral replication cycle. Some older members
of the retrovirus family have found their way into the
vertebrate germ line while current members seem to
remain exogenous. Vertebrate genomes contain substan-
tial amounts of retroviral sequences in various states of
inactivation since their integration (for a review on the
discovery, see [1]). Integrated endogenous retrovirus
(ERV) genomes commonly contain mutations, deletions,
or are even reduced to single long terminal repeat
(LTR) elements by homologous recombination between
the two LTR’s. More recent integrations usually have
retained at least partial coding capacity. Some integrated
ERV elements have been adopted and are used to the
hosts’ advantage, either as a novel regulatory sequence,
a novel protein, or as a means to protect against new
retrovirus infections (reviewed by [2]). This latter
mechanism is called superinfection resistance (SIR), and
works best against closely related retroviruses by simple
mechanisms such as receptor occupancy (reviewed by
[3]).
Around 8% of the human genome is of retroviral ori-
gin, which includes proviruses that belong to beta-,
gamma-, and spuma- retroviruses (Figure 1). Human
endogenous retroviruses (HERVs) are historically classi-
fied by the tRNA specificity of their primer binding site
(PBS), which can be confusing as unrelated species may
share the same tRNA primer for reverse transcription
[4]. Many HERV elements may have lost the ability to
transfer, but several retain the capability to be tran-
scribed and translated under certain conditions, includ-
ing embryonic development and disease [2]. The most
recent and widespread human integrations belong to
retroviruses with homology to mouse mammary tumour
virus (MMTV, a betaretrovirus) and are known as the
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recent review, see [5]). Full-length proviral genomes of
HML-2 family members are present, but these are not
replication competent, even the HERV-K113 element
that retains full coding capacity [6]. The human germ
line tumour cell Tera-1 even produces (non-infectious)
retrovirus particles containing HML-2 RNA, but the
assembly of these particles was found to depend on
trans-acting viral proteins and RNA genomes derived
f r o mam o s a i co fH M L - 2p r o v i r a lg e n o m e s[ 7 ] .T h e
human mammary carcinoma cell line T74-D was found
to release virions with B-type morphology that also con-
tain retroviral transcripts originating from different loci
[8]. Infectious HML-2 viruses have now been recon-
structed in the laboratory to delineate their characteris-
tics [9,10].
Humans are currently threatened by only two exogen-
ous retrovirus species: human T-cell lymphotropic virus
(HTLV, a deltaretrovirus) and human immunodeficiency
virus (HIV, a lentivirus). A third putative human
Figure 1 Phylogenetic tree of human retroviruses. A 183 translated amino acid fragment surrounding the YXDD motif in the pol gene shows
the relationship between endogenous and exogenous retroviruses of humans. Sequences were retrieved from the GenBank database [83],
translated and aligned using BioEdit version 7.0 [84]. A phylogenetic tree with 500 bootstrap replicates was constructed with the neighbour-
joining method based upon a distance matrix generated with the Poisson model for amino acid substitutions while assuming uniform rates
among sites, as implemented in MEGA 5.0 [85]. Schematic genome organizations for different classes of retroviruses are shown. Drawings are not
to scale. Additional reading frames may exist in other strains (e.g. non-primate lentiviruses encode a dUTPase). Abbreviations: HERV = human
endogenous retrovirus; HIV = human immunodeficiency virus; HTLV = human T-cell lymphotropic virus; SFV = simian foamy virus. Accession
numbers: AF074086 (HERV-K HML-2); NC_001436 (HTLV-1); M10060 (HTLV-2); K03455 (HIV-1); M15390 (HIV-2); U04327 (SFV); NT_029419 (from
which a HERV-E Pol sequence was retrieved). Analysed but not shown: AF033807 (MMTV, a betaretrovirus); J01998 (MuLV, a gammaretrovirus);
M12349 (simian Mason-Pfizer monkey virus, a deltaretrovirus); DQ399707 (XMRV, a gammaretrovirus), and the horse endogenous betaretrovirus
EqERV-beta 1 [86]. LTR = long terminal repeat, consisting of the U3, R and U5 regions in the integrated provirus, gag = group-specific-antigen,
du = dUTPase, pro = protease, pol = polymerase (reverse transcriptase and integrase), env = envelope, bel 1-3 (bel 1 is also known as tas; the bel
2 reading frame overlaps with another one named bet), tax, rex, tat, rev, vpu, vif, nef and vpr encode small additional proteins. The HERV-K Rec
protein is also known as K-Rev. HERV-K rec is found in HERV-K type II proviruses, while np9 is encoded by HERV-K type I proviruses [87]. In
spumavirus, either gag-pro or pro-pol are encoded in the same translational reading frame.
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virus (XMRV, a gammaretrovirus) has recently been dis-
carded as a contaminant [11,12]. No sequences with
homology to delta- or lenti- viruses have been found in
the human genome, although endogenous lentivirus
genomes were discovered in basal primates [13,14].
Infection with the spumavirus simian foamy virus (SFV)
occurs occasionally in persons exposed to non-human
primates, but the virus does not seem to spread among
humans [15-17]. The only described human endogenous
retrovirus element with (distant) homology to foamy
viruses is HERV-L [18].
In this review, the effect of infection with an exogen-
ous retrovirus (HIV) on the resident endogenous virus
population will be summarized with regard to viral gen-
ome expression, possible complementation, and immune
response.
Complementation of HERV and HIV proteins
All retroviruses have a similar genetic make-up, whereby
long terminal repeat (LTR) regulatory sequences flank
the reading frames for Gag, Pol, and Env proteins. Gag
and Pol are processed by the viral protease into smaller,
functional proteins, while a cellular protease processes
Env. The Pol polyprotein is cleaved into the protease
(PR), reverse transcriptase (RT), and integrase (INT)
enzymes. Homologous proteins encoded by one retro-
virus could theoretically perform comparable functions
in trans for another member of the family, and could
thus complement a (defective) virus. Examples of possi-
ble complementation between HERV and HIV proteins
will be discussed next.
A first example of a potential supplementary function
is the dUTP pyrophophatase (dUTPase) enzyme. In
betaretroviruses, a dUTPase domain is present at the N-
terminal part of the protease. In non-primate exogenous
lentiviruses, the dUTPase domain is located between the
RNase H domain and the integrase coding region of the
pol gene. Such dUTPase activity is essential for retro-
virus replication by reducing the levels of dUTP during
cDNA synthesis, thereby minimizing the incorporation
of dUTP into the nascent DNA by the reverse transcrip-
tase. In contrast to all other lentiviruses, exogenous pri-
mate lentiviruses (simian immunodefiency virus, SIV,
and HIV) lack a dUTPase and depend upon the cellular
uracil DNA-glycosylase UNG2 to provide this function
[19]. Some researchers have suggested that HIV-1 can
efficiently replicate without UNG2 [20], because it toler-
ates heavily uracilated DNA. Alternatively, the dUTPase
encoded by active HERV-K proviruses could supply this
function [21]. Interestingly, the endogenous lentivirus
elements carried by lemurs do contain a dUTPase gene
[13,14], suggesting that this function was specifically lost
in the extant SIV lineage.
When protease inhibitors specifically designed to inhi-
bit the HIV-PR enzyme were included in the drug regi-
men offered to HIV-infected patients, there was some
concern as to whether endogenous proteases, likely
resistant to the anti-HIV drugs because of remote
amino acid similarity, would be able to trans-comple-
ment the targeted enzyme. HERV-K10 protease is
indeed highly resistant to HIV-PR inhibitors and able to
process the HIV gag matrix-capsid protein at the
a u t h e n t i cc l e a v a g es i t e[ 2 2 ] .H o w e v e r ,w h e naH E R V - K
PR was incorporated into virions of a PR-defective HIV-
1 strain, no complementation was achieved [23]. The
Gag-Pol precursors were found to be processed at unna-
tural sites, rendering the produced virion particles non-
infectious. When HERV-K PR was incorporated into
wild type (wt) HIV-1 virions with the intention to
decrease their infectivity, no deleterious effect was seen,
and only small fractions of aberrantly cleaved proteins
were detected [23].
HERV-K10 INT has been reported to be able to com-
plement an INT-defective HIV-1 strain, although infec-
tivity was severely reduced to 3.7% of wt HIV-1 [24]. It
is nevertheless remarkable that HERV-K10 INT was
able to recognize the dissimilar HIV-1 LTR sequences
to achieve in vitro integration levels of 10-30% of HIV-1
INT.
Retroviral envelope proteins are quite versatile and can
often be used to package dissimilar viral genomes (pseu-
dotyping). A few HERV envelope genes, such as the
gammaretroviral HERV-W derived envelope protein,
syncytin, that plays a role in the attachment of the
human placenta, are expressed in vivo [25,26]. HERV-W
Env can still function as a viral envelope protein, as
infectious particles were generated when it was used to
complement an env-defective HIV-1 strain [27]. The
HERV-W pseudotyped particles were infectious for
CD4-negative cells, suggesting a mechanism by which
HIV-1 can expand its cellular tropism during natural
infection. Interestingly, env-deficient HIV-1 cannot be
complemented by the Env protein of murine leukaemia
virus (MuLV), also a gammaretrovirus [26,27]. In con-
trast, the generation of pseudotypes between HIV-1 and
endogenous xenotropic MuLVs was proposed earlier as
an explanation for the increased tropism of HIV-1 parti-
cles harvested from a cell line that had been passaged in
immunosuppressed mice [28].
Some classes of retroviruses, termed complex retro-
viruses, encode several accessory proteins that simple
retroviruses lack. For instance, HIV-1 encodes at least 6
additional proteins, betaretroviruses generally only one,
and gammaretroviruses commonly none. An essential
additional protein that assists in transporting unspliced
and incompletely spliced viral mRNAs from the nucleus
to the cytoplasm is named Rev in HIV-1 and Rex in
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RNA structure in Env-encoding sequences that is
denoted the Rev responsive element (RRE). A homolog
of Rev/Rex is encoded by HERV-K, where it is termed
K-Rev or Rec [29]. To some extent, Rev/Rex proteins
from complex retroviruses can complement each other,
e.g. the Rex protein of HTLV-1 can functionally replace
the HIV-1 Rev protein [30]. However, Rev/Rex comple-
mentation studies are not always straightforward
because results often depend upon the experimental sys-
tem used (see e.g. [31] and references therein). HIV-1
Rev can bind the HERV-K RRE, but the reverse is not
true as K-Rev does not interact with the HIV-1 RRE
[29]. Thus, although no actual complementation studies
between HIV-Rev and K-Rev have been performed, it is
unlikely that K-Rev can complement HIV-1 Rev because
RRE binding is essential for protein function. Patients
harbouring viral genomes with a rev defect or attenuat-
ing mutations have been described [32-34]. The disease
phenotype in these patients is generally mild, suggesting
that Rev defects in vivo are indeed not (completely)
resolved by endogenous K-Rev.
No HERV RNA in HIV-1 virions?
Retrovirus particles contain, apart from two copies of
the viral RNA genome, spliced viral RNA’s, several
tRNAs, and varying amounts of cellular mRNAs that are
co-packaged in a concentration dependent manner
[35-37]. Some of the cellular RNAs, such as those cod-
ing for ribosomal proteins, are preferentially packaged in
HIV virions [35]. If HERV RNA would be co-packaged
into HIV-1 virions, this could result in effective mobili-
zation of these elements. This was investigated in several
packaging cell lines used in retroviral vector systems.
Zeilfelder et al. showed that HIV-1 derived vectors sys-
tems incorporate very little HERV transcripts in parti-
cles in contrast to murine leukaemia virus (MLV) based
vectors [38]. Although the system used by Zeilfelder et
al. is highly artificial, it nevertheless suggests that HIV-1
does not readily encapsidate HERV transcripts or gen-
omes. An explanation could be that HIV-1 Gag does
not recognize the RNA packaging signals carried by the
non-lentiviral HERVs, while MLV Gag is able to bind to
the more related HERV sequences.
Increase of HERV viral RNA after HIV-1 infection
In vitro HIV-1 infection of either CD4 expressing T- cell
lines or stimulated peripheral blood mononuclear cells
(PBMC’s) upregulates the production of HERV-K RNA
and proteins compared to non-infected cells [39]. Analy-
sis of blood plasma samples from HIV-1 infected
patients also showed a significant increase of HERV-K
RNA expression [40,41], with titers as high as 10
6-10
10
copies/ml [42]. In > 95% of samples HERV-K pol RNA
was found compared to only 5-8% of the control sam-
ples, which included hepatitis C virus (HCV) infected
patients and healthy individuals [40]. In contrast,
HERV-H RNA, which is upregulated in rheumatoid
arthritis patients, was not detected in HIV-1 infected
blood plasma [40]. The majority of the HERV tran-
scripts in HIV-1 infected samples belonged to the
HERV-K (HML-2) family and a minority to the HERV-
K (HML-3) cluster. These HERV-K transcripts were
d e r i v e df r o ms e v e r a lg e n o m i cl o c i ,b u tt r a n s c r i p t sf r o m
the HML-2 type-2 provirus located at chromosome
4q35 predominated [42]. HML-2 type 1 and type 2 pro-
viruses differ from each other by a 292 nt deletion in
the env gene that disables the expression of functional
protein in type 1. Further analysis suggested that the
observed transcripts likely represent full-length viral
RNAs that are protected from degradation by Gag pro-
tein [40]. Indeed, immature virus particles that reacted
only with anti-Gag Ig were observed using electron
microscopy in a follow-up study, although mature viral
particles reacting with anti-HERV-K Env antibodies and
possessing condensed cores and symmetrically distribu-
ted spikes were also occasionally present in the blood
plasma of HIV-1 infected patients [42]. HERV-K recom-
binant genomes were detected in blood plasma from
some HIV-1 infected patients but not in breast cancer
patients. Furthermore, genetic variation was observed in
env (primarily synonymous substitutions indicative of
purifying selection), with preservation of glycosylation
sites together suggestive of replication through reverse
transcription [42].
Laderoute et al. focussed on a HERV-K102 member of
the HML-2 family that is upregulated during HIV-1
infection [43]. They reported that ~ 76% of blood
plasma samples of HIV-1 infected patients test positive
for particle associated HERV-K102 pol transcripts, ver-
sus ~ 3% of healthy controls. However, ~ 79% and ~
62% of individuals with hepatitis B virus (HBV), hepati-
t i sCv i r u s( H C V )o rh e r p e sv i r e m i aa l s os h o w e d
increased particle associated HERV-K102 pol transcript
expression [43], suggesting a more general mechanism
of HERV-K upregulation due to virus infection and
immune stimulation. HERV-K upregulation was inde-
pendent of ethnicity as it was seen both in individuals of
European and African descent [43].
In contrast, high throughput sequencing of transcripts
f r o mH I V - 1i n f e c t e dv e r s u su n i n f e c t e dc e l l sd i dn o t
demonstrate a significant increase in HERV expression
upon HIV-1 infection [44]. Possibly, the genetically
highly aberrant SupT1 T-cell line used in these experi-
ments can account for this unexpected result. Either
HERV expression could already be at peak level before
HIV infection of these cells, or specific HERV integra-
tions could simply be absent. Alternatively, the vesicular
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HIV particles used could possibly explain the lack of
HERV induction, as Contreras-Galindo et al. [39] used
complete HIV-1 viral particles in their infection assays.
Besides, virus infection conditions differed significantly
between the experiments.
A significant upregulation of HERV-W and HERV-K
RNA was detected in brain tissue from patients with
AIDS dementia, whereas HERV-E expression was
decreased [45]. The changes in HERV expression were
associated with monocyte differentiation and macro-
phage activation.
HERV expression during antiretroviral therapy
As mentioned before, HERV-K RNA expression is
increased in a dose-dependent manner by infection of
peripheral blood mononuclear cells (PBMC’s) and var-
ious cell lines with HIV-1 viral particles [39]. In vivo,i t
has not been examined whether HERV-K RNA levels
increase during acute or chronic HIV-1 infection.
Highly-active antiretroviral therapy (HAART) against
HIV decreases the HIV plasma viral load (pVL) to < 50
copies/ml in most patients. Quantifying the HERV-K
RNA load in patients receiving HAART confirmed that
the HERV-K load is linked to the HIV-1 pVL. Patients
that showed a good suppression of HIV-1 replication
had a HERV-K load that was around two orders of mag-
nitude lower than the average HERV-K load in patients
with less efficient HIV-1 suppression [46]. HERV-K102
particle-associated nucleic acid could not be measured
in five patients on antiretroviral therapy (four of them
with good control of the HIV-1 pVL) in another study,
in contrast to patients not receiving antiretroviral ther-
apy [43].
Longitudinal analysis of patients receiving HAART
demonstrated the long-term suppression of the HERV-K
pVL to < 5000 copies/ml when the HIV-1 pVL
remained below 50 copies/ml [47]. When patients failed
HAART, the HERV-K pVL increased rapidly, frequently
preceding the HIV-1 pVL rebound [47]. It is unclear
whether HERV-K is (partially) inhibited by the antiretro-
viral drugs, or whether the loss of activation by HIV-1,
or possibly another mechanism, is responsible for the
reduction in HERV-K load. Protease inhibitors targeted
at HIV are not active against the HERV-K enzyme [22],
but other classes of antiretroviral drugs, in particular the
nucleotide analogues that target the RT enzyme, might
be. It is, however, not likely that the HERV-encoded
reverse transcriptases are appreciably involved in the
increase in HERV load, as copy numbers of both intact
RT genes encoding functional proteins as well as intact
primer binding sites (PBS) and other motifs needed to
initiate reverse transcription, such as the primer activa-
tion domain (PAS) in HIV, are likely to be low. Also,
RT enzymes prefer certain tRNA molecules for initiation
of replication and e.g. HIV-1 RT has decreased activity
when using other tRNA/PBS combinations [48,49]. This
preference suggests that RT activity on non-self tem-
plates is probably greatly reduced, disabling the reverse
transcription of non-family members.
Interestingly, the non-nucleoside RT inhibitors nevira-
pine and efavirenz can efficiently inhibit endogenous RT
activity that is detectable in many human cell lines and
leukaemic cells, thereby attenuating the malignant phe-
notype of the cells [50,51]. Nevirapine was not active
against LINE-1 retroposon-encoded RT, whereas several
nucleoside analogue RT inhibitors did inhibit LINE-1
RT, albeit with varying degrees of efficacy [52].
Mechanisms of HERV activation by HIV infection
It is not clear what the precise mechanism of HERV
induction by HIV infection is. HERV expression is sup-
pressed in the germ-line and during the first steps of
embryogenesis, while it is controlled during cell devel-
opment (reviewed in [53]). Increased HERV expression
is often seen during carcinogenesis and in autoimmune
diseases such as multiple sclerosis [2], but it is unclear
whether the increased expression is a cause or conse-
quence of the disease. HERVs including the HERV-K
(HML-2) family [54] and HIV-1 proviruses [55] are nor-
mally transcriptionally silenced by CpG methylation that
is subsequently guarded by DNA methyltransferase 1
(DNMT1) (reviewed in [53]). Loss of methylation results
in activation of proviruses, either HERV or HIV, but it
has not been investigated whether HIV actively influ-
ences proviral methylation levels. HERV expression in
HIV-infected cells could be enhanced if methylation
levels of proviral DNA are reduced by HIV. Other inves-
tigators proposed a more complex mechanism for the
induction of HIV-1 latency that employs transcriptional
interference [56,57]. Several mechanisms may cooperate
to restrict HIV provirus activation [58]. It is not clear
whether changes in the pool of available transcription
factors modulates HERV expression. Many HERV LTR
promoters are probably not fully functional, e.g. not able
to bind these transcription factors, and thus do no
longer require such a repressive mechanism. Addition-
ally, the HIV-1 proviral integration site location might
also select for viral latency, virus induction or stable
expression [59]. Generally, HIV-1 favours integration
into transcriptionally active genes, usually in introns
that are part of local transcription hotspots, without
apparent directional bias [60]. In contrast, HERV pro-
viruses are generally found outside genes, and com-
monly in the reverse orientation compared to the
nearby cellular gene. HERV integrations seen in contem-
porary genomes are the result of stringent evolutionary
selection, whereby HERV’s in the sense orientation
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cellular genes were probably negatively selected for [60].
In other words, observed HERV integrations do prob-
ably not faithfully reflect HERV target site preferences.
Anyhow, the consequence is that HIV-1 proviruses are
rarely found in the proximity of HERV integrations
[59,60], ruling out that there is a direct positional effect
of HIV-1 transcription upon HERV activation.
Specific upregulation of en d o g e n o u sp r o v i r u s e sb y
HIV proteins or cellular proteins upregulated by HIV is
another possibility. It has been suggested that the HIV-1
Tat protein is able to directly activate the HERV-K
(HML-2) LTR [47]. The HTLV-I encoded transactivator
protein Tax is likewise able to activate HERV LTRs,
mainly of HERV-W and HERV-H [61]. HERV-K (HML-
2) RNA is not, or only weakly, upregulated by common
stimulation of donor PBMCs with phytohaemagglutinin,
gamma irradiation or 5-azacytidine [62], suggesting that
HERV upregulation requires undefined, yet specific
conditions.
Another indirect mechanism of HERV upregulation by
HIV-1 infection could be through opportunistic viral
infections. HIV infection deregulates and eventually
destroys the immune system. Loss of immune control
facilitates the replication of diverse opportunistic patho-
gens. Some of these pathogens, e.g. herpesviruses, are
virtually ubiquitous in the human population and
remain latently present during the lifetime of the host.
Herpesviruses are reactivated from latency during
chronic HIV infection [63]. Herpes simplex virus type 1
(HSV-1) can specifically activate the HERV-W LTR, and
induce expression of HERV-W Gag and Env proteins in
cell lines [64-66]. Epstein-Barr virus (EBV), that has a
prevalence rate of around 75% in humans, induces tran-
scription of the env gene of HERV-K18 [67], and so do
human herpesvirus 6A [68] and 6B [69]. Most likely, the
other five human herpesviruses are also able to activate
HERV transcription. HHV-6 and human herpesvirus 7
(HHV-7), that have infection rates of 100% each in the
human population, infect, similar to HIV, CD4
+ T-cells,
and could thus (partly) be responsible for HERV induc-
tion seen in PBMC’s after HIV-1 infection. EBV com-
monly infects B-cells, while cytomegalovirus (CMV),
with a prevalence rate of around 50%, infects monocytes
and macrophages, and both could likewise contribute to
the observed rise in PBMC HERV expression. In addi-
tion, infection by influenza A virus enhanced HERV-W
expression in cell culture as well [66], suggesting that
many more viruses have the potential to do so.
Expression of the HIV accessory protein Vif counter-
acts the viral restriction factor APOBEC3G and could
result in abrogation of cellular HERV control [70] and
de novo replication of HERV elements by reverse tran-
scription. Restriction during reverse transcription by
APOBEC3G was shown for HERV-K (HML-2) elements,
both during in vitro replication as well as in the muta-
tion pattern of ancient integrations [71,72].
HERV proteins and antibodies in HIV infected
patients
Increased expression of HERV-K Gag protein has been
detected in both the CD4
+ and CD8
+ T-cell fractions
from HIV-infected patients compared to T-cells from
uninfected individuals [39]. It is remarkable that HERV-
K Gag is also upregulated in CD8
+ T-cells that are nor-
mally not infected by HIV-1, which would suggest a
more general and indirect mechanism of activation. No
significant correlation was found between the HIV-1
pVL, CD4
+ or CD8
+ T-cell counts and HERV-K protein
titers.
Antibodies to expressed HERV-K proteins are fre-
quently found in several groups of patients, which is
interesting because HERVs should be classified as self-
antigens. Some studies did describe a HERV-K antibody
response in HIV-1 infected persons, while others did
not. No significant increase in serum antibodies against
recombinant human teratocarcinoma-derived virus
(HTDV)-HERV-K Env protein was seen in HIV-1
infected patients (15.2% versus 12.6% in healthy con-
trols) [73]. Similar negative results were obtained by
Vogetseder et al. [73] and Boller et al. [74], when exam-
ining the antibody response against HTDV/HERV-K
Gag and Env proteins in HIV-1 positive individuals, and
by Goedert et al. [75] in HIV-1 infected individuals with
testicular cancer. In contrast, 70% of HIV-1 infected
patients versus 3% of healthy controls tested positive for
antibodies against HTDV/HERV-K Env in a fourth
study [76]. A fifth study, employing HERV-K102 Env
peptide serology reported similar numbers, with 70-80%
of HIV-1 viraemic patients testing positive versus 2% of
healthy controls and 18% of patients with herpes virae-
mia [43]. Interestingly, a patient seroconverting for anti-
HIV-1 antibodies showed a parallel seroconversion for
anti-HERV-K Env antibodies in the study by Vogetseder
et al. [73]. Cross-reactivity is unlikely to explain this
result, as the HERV-K and HIV-1 Env proteins have lit-
tle amino acid similarity.
Testing urine specimens of HIV-1 infected individuals
and healthy controls for antibodies against a peptide
derived from the gammaretrovirus HERV-E Env protein
showed that 36.4% and 81.3% of patients in the CDC
AIDS categories A and B/C respectively, contained spe-
cific antibodies, while none of the HIV-negative controls
tested positive [77]. Fourteen peptides derived from var-
ious endogenous retroviruses were used to search for
IgM and IgG antibodies in HIV-1 infected and unin-
fected immunosuppressed persons by Lawoko et al.
[78]. Three peptides, corresponding to the C-terminal
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conserved domain of the HERV-H transmembrane
domain, and part of HERV-K HML-3 encoded Pol, were
found to bind IgG in both groups, with stronger binding
of the latter two peptides in HIV-1 infected patients
[78]. No correlation of either IgM or IgG binding with
progression to AIDS was observed.
In conclusion, it is difficult to summarize these studies
on anti-HERV antibodies in HIV-1 infected patients.
Studies on HERV-K remain contradictory, while others
investigated HERV families whose RNA expression
levels during HIV infection have not been characterized.
T-cell response to HERV in HIV infected patients
Although HERV proteins should be regarded as self-
antigens, tolerance is often broken during neoplastic
processes and also during HIV infection as demon-
strated by a study that measured T-cell responses
against HERV during HIV infection [41]. Peptides corre-
sponding to HERV and HIV epitopes were tested for
their ability to evoke a T-cell response in vitro. Ten pep-
tides contained short regions of homology between
HERV-H/-K/-L and HIV, respectively, and six others
unique for HERV-L or HERV-W were used to estimate
both putative cross-reactive and virus-specific T-cell
responses. HERV-H and HERV-W cluster with the gam-
maretroviruses, and HERV-L has similarity to spuma-
viruses [79]. PBMC samples were collected from HIV-1
infected, HCV infected, and uninfected individuals. T-
cell responses against HERV epitopes were detected
only in HIV-1 positive patients, with no significant dif-
ference in reactions against unique HERV peptides ver-
sus HIV-related HERV peptides. This suggests that the
r e s p o n s ea g a i n s tH E R Ve p i t o p e si sd i s t i n c tf r o mt h e
anti-HIV response. T-cell cross-reactivity was tested in
three patients with a response to either the HIV-RT
VL9 or HERV-L II9 peptide which share some amino
acid similarity, but was found to be absent.
Anti-HERV T cell responses were broad and varied
significantly among the study subjects [41]. The HERV-
specific T-cell responses were inversely correlated with
the HIV-1 pVL, raising the exciting possibility that these
responses could be involved in the control of HIV repli-
cation. Reactivity to the unique HERV-L IQ10 peptide
was found in 5/16 HIV-1 infected patients. Longitudinal
analysis of three patients showed persistent responses to
this peptide that declined in two patients when HAART
was started. The third patient with the highest response
to this peptide controlled HIV replication without ther-
apy. HERV-specific CD8
+ T-cells were able to lyse cells
presenting the corresponding peptide. If HIV-1 infected
cells that present HERV peptides are subsequently lysed
by HERV-specific CD8
+ T-cells, a decrease in HIV-1
pVL would be the result, explaining the observations in
the three patients described above. In a follow-up study,
anti-HERV T-cell responses were analysed in a larger
cohort of untreated HIV-1 infected individuals [70]. The
breadth and magnitude of the HERV response were
again inversely correlated with HIV-1 pVL and positively
associated with CD4
+ T-cell counts. The peptide that
evoked the largest number of responses was derived
from HERV-H Env. Other peptides tested originated
from HERV-K (n = 14), HERV-L (n = 12), and HERV-
W (n = 1).
An HIV-1 positive patient who controlled the infec-
tion for over 8 years showed HLA-B51 restricted
responses to the HERV-K Pol epitope FAFTIPAI as well
as to the corresponding HIV-1 epitope TAFTIPSI. The
CD8
+ T-cells responding to the HERV epitope were
found to be less activated and more differentiated than
the cells targeting the HIV-1 epitope [70]. The cytome-
galovirus-specific CD8
+ T-cell population in this patient
did mimic the HERV response.
Overall, these results suggest that a robust CD8
+ T-
cell response against the newly expressed HERV pep-
tides presented by HIV infected cells may contribute to
the control of HIV replication in blood. Indeed, a sec-
ond study in vertically infected children showed a simi-
lar outcome: anti-HERV responses were inversely
correlated with the HIV-1 plasma viral load and posi-
tively correlated with the CD4
+ T cell count [80]. Alter-
natively, Tandon et al. suggest that instead of a direct
effect of anti-HERV responses, the correlations might be
related to a more intact immune system in patients
showing considerable anti-HERV activity.
Anti-HERV vaccines as an approach to combat
HIV?
T-cell responses that are effective in lowering the HIV-1
pVL and thus assist in controlling HIV replication are
potential vaccine targets. In contrast to the replicating
and rapidly mutating HIV-1 genome, HERVS are cellu-
lar genes that are not prone to mutation. Although
HERV integrations are present in every cell in the body,
they are expressed in a cell type and development speci-
fic way, making many HERV proteins rather specific
antigens. Indeed, a HERV-K env transcript, HERV-K-
MEL, encoded a melanoma-specific antigen that was
recognized by cytolytic T lymphocytes [81]. Vaccination
with peptides derived from another melanoma-specific
antigen had been successful earlier in inducing tumour
regression (see [81]), suggesting that vaccination with
HERV-K-MEL peptides could be an effective strategy. A
HERV-E transcript specifically expressed by renal cell
carcinoma tissue and cell lines encoded a peptide that
was recognized by CD8
+ T-cells after allogeneic hemato-
poietic stem cell transplantation [82]. Recognition
resulted in tumour regression in vivo, an example of the
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malignancy.
The research performed by Garrison et al.[ 4 1 ] ,S e n -
Gupta et al. [70], and Tandon et al. [80] suggests that a
similar approach is possible in HIV-1 infection. T-cell
responses targeted at HERVs expressed by HIV-1
infected cells could be helpful in killing those cells.
However, before embarking on the HERV approach,
several basic issues need to be addressed. It is currently
unclear which HERV epitopes are expressed by HIV-
infected cells, at what magnitude and at what specificity.
SenGupta et al. recorded CD8
+ T-cell responses against
multiple HERV families in HIV-1 infected patients,
including HERV-H, -K, -L, and -W [70]. HERV epitope
recognition was found to vary among individuals, com-
plicating the generation of a universal vaccine. It is also
uncertain whether the discovered epitopes are expressed
exclusively by HIV-1 infected cells, or whether there is
also an indirect bystander effect on non-infected cells as
reported by Contreras-Galindo et al. [39]. Furthermore,
it is not clear if a similar pattern of HERV expression is
apparent in all HIV-1 susceptible cell types e.g. in CD4
+
T-cells and monocytes. These issues need to be
addressed in vitro and combined with the analysis of
patient samples before HERV-vaccination approaches
can be developed further.
Conclusions
Infection of humans with the retrovirus HIV-1 has pro-
found effects upon the resident, endogenous retro-
viruses. Transcripts and proteins representing diverse
classes of endogenous retroviruses are upregulated.
Direct interactions between HERVs and HIV-1 are lim-
ited as indicated by the lack of complementation, which
probably relates to the low sequence similarity. Induc-
tion of certain HERV epitopes on HIV-1 infected cells
renders these cells susceptible to lysis by CD8
+ T-cells,
constituting a possible mechanism to control HIV-1
infection. It has been proposed to translate these obser-
vations into a vaccination approach with stable HERV-
based antigens, but the detailed knowledge on the mag-
nitude and specificity of HERV expression in HIV-1
infected cells is prerequisite for such applications.
Acknowledgements
The author thanks Ben Berkhout and Marion Cornelissen for critical reading
of the manuscript.
Authors’ contributions
ACvdK conceived the review topic and drafted the manuscript.
Competing interests
The author declares that she has no competing interests.
Received: 9 December 2011 Accepted: 16 January 2012
Published: 16 January 2012
References
1. Weiss RA: The discovery of endogenous retroviruses. Retrovirology 2006,
3:67.
2. Kurth R, Bannert N: Beneficial and detrimental effects of human
endogenous retroviruses. Int J Cancer 2010, 126:306-314.
3. Nethe M, Berkhout B, van der Kuyl AC: Retroviral superinfection resistance.
Retrovirology 2005, 2:52.
4. Blomberg J, Benachenhou F, Blikstad V, Sperber G, Mayer J: Classification
and nomenclature of endogenous retroviral sequences (ERVs): problems
and recommendations. Gene 2009, 448:115-123.
5. Mayer J, Meese E: Human endogenous retroviruses in the primate
lineage and their influence on host genomes. Cytogenet Genome Res
2005, 110:448-456.
6. Beimforde N, Hanke K, Ammar I, Kurth R, Bannert N: Molecular cloning and
functional characterization of the human endogenous retrovirus K113.
Virology 2008, 371:216-225.
7. Ruprecht K, Ferreira H, Flockerzi A, Wahl S, Sauter M, Mayer J, et al: Human
endogenous retrovirus family HERV-K(HML-2) RNA transcripts are
selectively packaged into retroviral particles produced by the human
germ cell tumor line Tera-1 and originate mainly from a provirus on
chromosome 22q11.21. J Virol 2008, 82:10008-10016.
8. Seifarth W, Skladny H, Krieg-Schneider F, Reichert A, Hehlmann R, Leib-
Mosch C: Retrovirus-like particles released from the human breast cancer
cell line T47-D display type B- and C-related endogenous retroviral
sequences. J Virol 1995, 69:6408-6416.
9. Dewannieux M, Harper F, Richaud A, Letzelter C, Ribet D, Pierron G, et al:
Identification of an infectious progenitor for the multiple-copy HERV-K
human endogenous retroelements. Genome Res 2006, 16:1548-1556.
10. Lee YN, Bieniasz PD: Reconstitution of an infectious human endogenous
retrovirus. PLoS Pathog 2007, 3:e10.
11. van der Kuyl AC, Cornelissen M, Berkhout B: Of mice and men: on the
origin of XMRV. Frontiers in Microbiology 2010, 1:147.
12. Paprotka T, Delviks-Frankenberry KA, Cingoz O, Martinez A, Kung HJ,
Tepper CG, et al: Recombinant origin of the retrovirus XMRV. Science
2011, 333:97-101.
13. Gifford RJ, Katzourakis A, Tristem M, Pybus OG, Winters M, Shafer RW: A
transitional endogenous lentivirus from the genome of a basal primate
and implications for lentivirus evolution. Proc Natl Acad Sci USA 2008,
105:20362-20367.
14. Gilbert C, Maxfield DG, Goodman SM, Feschotte C: Parallel germline
infiltration of a lentivirus in two Malagasy lemurs. PLoS Genet 2009, 5:
e1000425.
15. Switzer WM, Bhullar V, Shanmugam V, Cong ME, Parekh B, Lerche NW, et al:
Frequent simian foamy virus infection in persons occupationally
exposed to nonhuman primates. J Virol 2004, 78:2780-2789.
16. Calattini S, Betsem EB, Froment A, Mauclere P, Tortevoye P, Schmitt C, et al:
Simian foamy virus transmission from apes to humans, rural Cameroon.
Emerg Infect Dis 2007, 13:1314-1320.
17. Jones-Engel L, May CC, Engel GA, Steinkraus KA, Schillaci MA, Fuentes A,
et al: Diverse contexts of zoonotic transmission of simian foamy viruses
in Asia. Emerg Infect Dis 2008, 14:1200-1208.
18. Cordonnier A, Casella JF, Heidmann T: Isolation of novel human
endogenous retrovirus-like elements with foamy virus-related pol
sequence. J Virol 1995, 69:5890-5897.
19. Priet S, Gros N, Navarro JM, Boretto J, Canard B, Querat G, et al: HIV-1-
associated uracil DNA glycosylase activity controls dUTP
misincorporation in viral DNA and is essential to the HIV-1 life cycle. Mol
Cell 2005, 17:479-490.
20. Yan N, O’Day E, Wheeler LA, Engelman A, Lieberman J: HIV DNA is heavily
uracilated, which protects it from autointegration. Proc Natl Acad Sci USA
2011, 108:9244-9249.
21. McIntosh EM, Haynes RH: HIV and human endogenous retroviruses: an
hypothesis with therapeutic implications. Acta Biochim Pol 1996,
43:583-592.
22. Towler EM, Gulnik SV, Bhat TN, Xie D, Gustschina E, Sumpter TR, et al:
Functional characterization of the protease of human endogenous
retrovirus, K10: can it complement HIV-1 protease? Biochemistry 1998,
37:17137-17144.
23. Padow M, Lai L, Fisher RJ, Zhou YC, Wu X, Kappes JC, et al: Analysis of
human immunodeficiency virus type 1 containing HERV-K protease. AIDS
Res Hum Retroviruses 2000, 16:1973-1980.
van der Kuyl Retrovirology 2012, 9:6
http://www.retrovirology.com/content/9/1/6
Page 8 of 1024. Ogata T, Okui N, Sakuma R, Kobayashi N, Kitamura Y: Integrase of human
endogenous retrovirus K-10 supports the replication of replication-
incompetent Int- human immunodeficiency virus type 1 mutant. Jpn J
Infect Dis 1999, 52:251-252.
25. Mi S, Lee X, Li X, Veldman GM, Finnerty H, Racie L, et al: Syncytin is a
captive retroviral envelope protein involved in human placental
morphogenesis. Nature 2000, 403:785-789.
26. Blond JL, Lavillette D, Cheynet V, Bouton O, Oriol G, Chapel-Fernandes S,
et al: An envelope glycoprotein of the human endogenous retrovirus
HERV-W is expressed in the human placenta and fuses cells expressing
the type D mammalian retrovirus receptor. J Virol 2000, 74:3321-3329.
27. An DS, Xie Y, Chen IS: Envelope gene of the human endogenous
retrovirus HERV-W encodes a functional retrovirus envelope. J Virol 2001,
75:3488-3489.
28. Lusso P, di M, Ensoli B, Franchini G, Jemma C, DeRocco SE, et al: Expanded
HIV-1 cellular tropism by phenotypic mixing with murine endogenous
retroviruses. Science 1990, 247:848-852.
29. Yang J, Bogerd HP, Peng S, Wiegand H, Truant R, Cullen BR: An ancient
family of human endogenous retroviruses encodes a functional
homolog of the HIV-1 Rev protein. Proc Natl Acad Sci USA 1999,
96:13404-13408.
30. Rimsky L, Hauber J, Dukovich M, Malim MH, Langlois A, Cullen BR, et al:
Functional replacement of the HIV-1 rev protein by the HTLV-1 rex
protein. Nature 1988, 335:738-740.
31. Sakai H, Siomi H, Shida H, Shibata R, Kiyomasu T, Adachi A: Functional
comparison of transactivation by human retrovirus rev and rex genes. J
Virol 1990, 64:5833-5839.
32. Iversen AK, Shpaer EG, Rodrigo AG, Hirsch MS, Walker BD, Sheppard HW,
et al: Persistence of attenuated rev genes in a human immunodeficiency
virus type 1-infected asymptomatic individual. J Virol 1995, 69:5743-5753.
33. Saurya S, Lichtenstein Z, Karpas A: Defective rev response element (RRE)
and rev gene in HAART treated AIDS patients with discordance between
viral load and CD4+ T-cell counts. J Clin Virol 2005, 33:324-327.
34. Churchill MJ, Chiavaroli L, Wesselingh SL, Gorry PR: Persistence of
attenuated HIV-1 rev alleles in an epidemiologically linked cohort of
long-term survivors infected with nef-deleted virus. Retrovirology 2007,
4:43.
35. Rulli SJ, Jr. Hibbert CS, Mirro J, Pederson T, Biswal S, Rein A: Selective and
nonselective packaging of cellular RNAs in retrovirus particles. J Virol
2007, 81:6623-6631.
36. Houzet L, Paillart JC, Smagulova F, Maurel S, Morichaud Z, Marquet R, et al:
HIV controls the selective packaging of genomic, spliced viral and
cellular RNAs into virions through different mechanisms. Nucleic Acids Res
2007, 35:2695-2704.
37. Didierlaurent L, Racine PJ, Houzet L, Chamontin C, Berkhout B, Mougel M:
Role of HIV-1 RNA and protein determinants for the selective packaging
of spliced and unspliced viral RNA and host U6 and 7SL RNA in virus
particles. Nucleic Acids Res 2011, 39:8915-8927.
38. Zeilfelder U, Frank O, Sparacio S, Schon U, Bosch V, Seifarth W, et al: The
potential of retroviral vectors to cotransfer human endogenous
retroviruses (HERVs) from human packaging cell lines. Gene 2007,
390:175-179.
39. Contreras-Galindo R, Lopez P, Velez R, Yamamura Y: HIV-1 infection
increases the expression of human endogenous retroviruses type K
(HERV-K) in vitro. AIDS Res Hum Retroviruses 2007, 23:116-122.
40. Contreras-Galindo R, Kaplan MH, Markovitz DM, Lorenzo E, Yamamura Y:
Detection of HERV-K(HML-2) viral RNA in plasma of HIV type 1-infected
individuals. AIDS Res Hum Retroviruses 2006, 22:979-984.
41. Garrison KE, Jones RB, Meiklejohn DA, Anwar N, Ndhlovu LC, Chapman JM,
et al: T cell responses to human endogenous retroviruses in HIV-1
infection. PLoS Pathog 2007, 3:e165.
42. Contreras-Galindo RA, Kaplan MH, Contreras-Galindo AC, Gonzalez-
Hernandez M, Ferlengui I, Giusti F, et al: Characterization of human
endogenous retroviral elements in the blood of HIV-1-infected
individuals. J Virol 2012, 86(1):262-76.
43. Laderoute MP, Giulivi A, Larocque L, Bellfoy D, Hou Y, Wu HX, et al: The
replicative activity of human endogenous retrovirus K102 (HERV-K102)
with HIV viremia. AIDS 2007, 21:2417-2424.
44. Lefebvre G, Desfarges S, Uyttebroeck F, Munoz M, Beerenwinkel N,
Rougemont J, et al: Analysis of HIV-1 expression level and sense of
transcription by high-throughput sequencing of the infected cell. J Virol
2011, 85:6205-6211.
45. Johnston JB, Silva C, Holden J, Warren KG, Clark AW, Power C: Monocyte
activation and differentiation augment human endogenous retrovirus
expression: implications for inflammatory brain diseases. Ann Neurol
2001, 50:434-442.
46. Contreras-Galindo R, Gonzalez M, Almodovar-Camacho S, Gonzalez-
Ramirez S, Lorenzo E, Yamamura Y: A new real-time-RT-PCR for
quantitation of human endogenous retroviruses type K (HERV-K) RNA
load in plasma samples: increased HERV-K RNA titers in HIV-1 patients
with HAART non-suppressive regimens. J Virol Methods 2006, 136:51-57.
47. Contreras-Galindo R, Almodovar-Camacho S, Gonzalez-Ramirez S, Lorenzo E,
Yamamura Y: Comparative longitudinal studies of HERV-K and HIV-1 RNA
titers in HIV-1-infected patients receiving successful versus unsuccessful
highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2007,
23:1083-1086.
48. Oude Essink BB, Das AT, Berkhout B: HIV-1 reverse transcriptase
discriminates against non-self tRNA primers. J Mol Biol 1996, 264:243-254.
49. Abbink TE, Beerens N, Berkhout B: Forced selection of a human
immunodeficiency virus type 1 variant that uses a non-self tRNA primer
for reverse transcription: involvement of viral RNA sequences and the
reverse transcriptase enzyme. J Virol 2004, 78:10706-10714.
50. Mangiacasale R, Pittoggi C, Sciamanna I, Careddu A, Mattei E, Lorenzini R,
et al: Exposure of normal and transformed cells to nevirapine, a reverse
transcriptase inhibitor, reduces cell growth and promotes differentiation.
Oncogene 2003, 22:2750-2761.
51. Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C, Beraldi R, et al:
Inhibition of endogenous reverse transcriptase antagonizes human
tumor growth. Oncogene 2005, 24:3923-3931.
52. Jones RB, Garrison KE, Wong JC, Duan EH, Nixon DF, Ostrowski MA:
Nucleoside analogue reverse transcriptase inhibitors differentially inhibit
human LINE-1 retrotransposition. PLoS ONE 2008, 3:e1547.
53. Rowe HM, Trono D: Dynamic control of endogenous retroviruses during
development. Virology 2011, 411:273-287.
54. Lavie L, Kitova M, Maldener E, Meese E, Mayer J: CpG methylation directly
regulates transcriptional activity of the human endogenous retrovirus
family HERV-K(HML-2). J Virol 2005, 79:876-883.
55. Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A,
et al: CpG methylation controls reactivation of HIV from latency. PLoS
Pathog 2009, 5:e1000554.
56. Lenasi T, Contreras X, Peterlin BM: Transcriptional interference
antagonizes proviral gene expression to promote HIV latency. Cell Host
Microbe 2008, 4:123-133.
57. Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, et al:
Determinants of the establishment of human immunodeficiency virus
type 1 latency. J Virol 2009, 83:3078-3093.
58. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D,
Pomerantz RJ: The challenge of finding a cure for HIV infection. Science
2009, 323:1304-1307.
59. Lewinski MK, Bisgrove D, Shinn P, Chen H, Hoffmann C, Hannenhalli S, et al:
Genome-wide analysis of chromosomal features repressing human
immunodeficiency virus transcription. J Virol 2005, 79:6610-6619.
60. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-1
integration in the human genome favors active genes and local
hotspots. Cell 2002, 110:521-529.
61. Toufaily C, Landry S, Leib-Mosch C, Rassart E, Barbeau B: Activation of LTRs
from different human endogenous retrovirus (HERV) families by the
HTLV-1 Tax protein and T-cell activators. Viruses 2011, 3:2146-2159.
62. Depil S, Roche C, Dussart P, Prin L: Expression of a human endogenous
retrovirus, HERV-K, in the blood cells of leukemia patients. Leukemia
2002, 16:254-259.
63. Griffiths PD: Herpesviruses and AIDS. J Antimicrob Chemother 1996,
37(Suppl B):87-95.
64. Lee WJ, Kwun HJ, Kim HS, Jang KL: Activation of the human endogenous
retrovirus W long terminal repeat by herpes simplex virus type 1
immediate early protein 1. Mol Cells 2003, 15:75-80.
65. Ruprecht K, Obojes K, Wengel V, Gronen F, Kim KS, Perron H, et al:
Regulation of human endogenous retrovirus W protein expression by
herpes simplex virus type 1: implications for multiple sclerosis. J
Neurovirol 2006, 12:65-71.
van der Kuyl Retrovirology 2012, 9:6
http://www.retrovirology.com/content/9/1/6
Page 9 of 1066. Nellaker C, Yao Y, Jones-Brando L, Mallet F, Yolken RH, Karlsson H:
Transactivation of elements in the human endogenous retrovirus W
family by viral infection. Retrovirology 2006, 3:44.
67. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT: Epstein-Barr virus
transactivates the human endogenous retrovirus HERV-K18 that encodes
a superantigen. Immunity 2001, 15:579-589.
68. Tai AK, Luka J, Ablashi D, Huber BT: HHV-6A infection induces expression
of HERV-K18-encoded superantigen. J Clin Virol 2009, 46:47-48.
69. Turcanova VL, Bundgaard B, Hollsberg P: Human herpesvirus-6B induces
expression of the human endogenous retrovirus K18-encoded
superantigen. J Clin Virol 2009, 46:15-19.
70. SenGupta D, Tandon R, Vieira RG, Ndhlovu LC, Lown-Hecht R, Ormsby CE,
et al: Strong human endogenous retrovirus-specific T cell responses are
associated with control of HIV-1 in chronic infection. J Virol 2011,
85:6977-6985.
71. Lee YN, Malim MH, Bieniasz PD: Hypermutation of an ancient human
retrovirus by APOBEC3G. J Virol 2008, 82:8762-8770.
72. Armitage AE, Katzourakis A, de OT, Welch JJ, Belshaw R, Bishop KN, et al:
Conserved footprints of APOBEC3G on hypermutated human
immunodeficiency virus type 1 and human endogenous retrovirus
HERV-K(HML2) sequences. J Virol 2008, 82:8743-8761.
73. Vogetseder W, Dumfahrt A, Mayersbach P, Schonitzer D, Dierich MP:
Antibodies in human sera recognizing a recombinant outer membrane
protein encoded by the envelope gene of the human endogenous
retrovirus K. AIDS Res Hum Retroviruses 1993, 9:687-694.
74. Boller K, Janssen O, Schuldes H, Tonjes RR, Kurth R: Characterization of the
antibody response specific for the human endogenous retrovirus HTDV/
HERV-K. J Virol 1997, 71:4581-4588.
75. Goedert JJ, Sauter ME, Jacobson LP, Vessella RL, Hilgartner MW, Leitman SF,
et al: High prevalence of antibodies against HERV-K10 in patients with
testicular cancer but not with AIDS. Cancer Epidemiol Biomarkers Prev
1999, 8:293-296.
76. Lower R, Lower J, Kurth R: The viruses in all of us: characteristics and
biological significance of human endogenous retrovirus sequences. Proc
Natl Acad Sci USA 1996, 93:5177-5184.
77. Stevens RW, Baltch AL, Smith RP, McCreedy BJ, Michelsen PB, Bopp LH,
et al: Antibody to human endogenous retrovirus peptide in urine of
human immunodeficiency virus type 1-positive patients. Clin Diagn Lab
Immunol 1999, 6:783-786.
78. Lawoko A, Johansson B, Rabinayaran D, Pipkorn R, Blomberg J: Increased
immunoglobulin G, but not M, binding to endogenous retroviral
antigens in HIV-1 infected persons. J Med Virol 2000, 62:435-444.
79. Jern P, Sperber GO, Blomberg J: Use of endogenous retroviral sequences
(ERVs) and structural markers for retroviral phylogenetic inference and
taxonomy. Retrovirology 2005, 2:50.
80. Tandon R, SenGupta D, Ndhlovu LC, Vieira RG, Jones RB, York VA, et al:
Identification of human endogenous retrovirus (HERV)-specific T cell
responses in vertically HIV-1-infected subjects. J Virol 2011,
85:11526-11531.
81. Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG: A human
endogenous retroviral sequence encoding an antigen recognized on
melanoma by cytolytic T lymphocytes. Cancer Res 2002, 62:5510-5516.
82. Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP,
et al: Regression of human kidney cancer following allogeneic stem cell
transplantation is associated with recognition of an HERV-E antigen by T
cells. J Clin Invest 2008, 118:1099-1109.
83. NCBI nucleotide database. [http://www.ncbi.nlm.nih.gov/nucleotide/].
84. BioEdit Sequence Alignment Editor version 7.0.9. [http://www.mbio.ncsu.
edu/BioEdit/bioedit.html].
85. MEGA 5 software package. [http://www.megasoftware.net/].
86. van der Kuyl AC: Characterization of a full-length endogenous beta-
retrovirus, EqERV-beta1, in the genome of the horse (Equus caballus).
Viruses 2011, 3:620-628.
87. Armbruester V, Sauter M, Krautkraemer E, Meese E, Kleiman A, Best B, et al:
A novel gene from the human endogenous retrovirus K expressed in
transformed cells. Clin Cancer Res 2002, 8:1800-1807.
doi:10.1186/1742-4690-9-6
Cite this article as: van der Kuyl: HIV infection and HERV expression: a
review. Retrovirology 2012 9:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
van der Kuyl Retrovirology 2012, 9:6
http://www.retrovirology.com/content/9/1/6
Page 10 of 10